Adjusted earnings were USD 1.42 on October 21, 2026. Abbott Laboratories stock costs EUR 87.23 on Oc

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $...

Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company, with the transaction expected to be completed by the end of 2027, subject to regulatory and corporate approvals. The proposed separation would create an independent business focused on nutritional products while allowing Abbott to concentrate on its medical devices, diagnostics and established pharmaceuticals operations.

Abbott Laboratories has today cut its 2026 sales growth forecast and said it plans to separate its nutrition business, which includes baby formula, into a publicly traded company.

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy. The Fund returned 2.41% in […]

Read Abbott Laboratories (ABT) Q3 FY2026 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information

Abbott plans to separate its nutrition business into an independent company, which is set to house electrolyte-beverage brand Pedialyte, as well as infant-formula brand Similac, with about $8.5 billion in annual sales.

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.